{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 102,
        "end": 111
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 129,
        "end": 133
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 205,
        "end": 209
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 163,
        "end": 187
      }
    },
    {
      "id": "T11",
      "obj": "Disease",
      "span": {
        "begin": 129,
        "end": 158
      }
    },
    {
      "id": "T12",
      "obj": "Disease",
      "span": {
        "begin": 205,
        "end": 234
      }
    },
    {
      "id": "T14",
      "obj": "Chemical",
      "span": {
        "begin": 163,
        "end": 174
      }
    },
    {
      "id": "T15",
      "obj": "Chemical",
      "span": {
        "begin": 177,
        "end": 187
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "22011650_9",
  "text": "CONCLUSIONS : HRQoL and symptom endpoints were consistent with efficacy outcomes in IPASS and favored gefitinib in patients with EGFR mutation-positive tumors and carboplatin / paclitaxel in patients with EGFR mutation-negative tumors ."
}
